Response to: Comment on: New-onset diabetes and impaired fasting glucose after liver transplant: risk analysis and the impact of tacrolimus dose.
Health Policy Research Center, Namazi Hospital,Shiraz University of Medical Science, Shiraz, Iran.
Kamran B
KB
Lankarani
Saman
S
Nikeghbalian
Parisa
P
Janghorban
Seyed Ali
SA
Malek-Hosseini
D001786:Blood Glucose / Q000187:drug effects*; D003920:Diabetes Mellitus / Q000453:epidemiology*; D005215:Fasting / Q000097:blood*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D016559:Tacrolimus / Q000009:adverse effects*
D001786:Blood Glucose; D007166:Immunosuppressive Agents; D016559:Tacrolimus